Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled and Parallel Group Trial to Evaluate Efficacy and Safety of Twice Daily Inhaled Doses of BI 1265162 Delivered by Respimat® Inhaler as add-on Therapy to Standard of Care Over 4 Weeks in Patients With Cystic Fibrosis - BALANCE - CF™ 1
Conditions
Interventions
BI 1265162
Placebo
Locations
26
United States
Nemours Children's Hospital
Orlando, Florida, United States
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Start Date
September 16, 2019
Primary Completion Date
April 16, 2020
Completion Date
April 24, 2020
Last Updated
June 4, 2021
NCT04469439
NCT06154447
NCT06984679
NCT02417740
NCT07484607
NCT05359991
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions